Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 6, 2004, Pages 2260-2266

  Lu, Liangjun ^a,b   Pilot Matias, Tami J ^a   Stewart, Kent D ^a   Randolph, John T ^a   Pithawalla, Ron ^a   He, Wenping ^a   Huang, Peggy P ^a   Klein, Larry L ^a   Mo, Hongmei ^a   Molla, Akhteruzzaman ^a  

^a ABBOTT LABORATORIES   (United States)

^b Building AP52 N ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BI 1; BI 2; CILUPREVIR; RNA DIRECTED RNA POLYMERASE; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BINDING SITE; DRUG POTENCY; DRUG RESEARCH; DRUG SCREENING; DRUG SENSITIVITY; DRUG STRUCTURE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; IC 50; IN VITRO STUDY; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN TERTIARY STRUCTURE; REPLICON; STRUCTURE ANALYSIS; TISSUE CULTURE; VIRUS GENOME; VIRUS MUTATION; WILD TYPE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CARBAMATES; CLONING, MOLECULAR; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; MACROCYCLIC COMPOUNDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTATION; PHENOTYPE; PLAQUE ASSAY; QUINOLINES; REPLICON; RNA, VIRAL; SERINE PROTEINASE INHIBITORS; THIAZOLES; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 2542467813     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.6.2260-2266.2004     Document Type: Article

References (32)

1. Barbato, G., D. O. Cicero, M. C. Nardi, C. Steinkuhler, R. Cortese, R. De Francesco, and R. Bazzo. 1999. The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism, J. Mol. Biol. 289:371-384.
2. Bartenschlager, R. 1999. The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy. J. Viral Hepat. 6:165-181.
3. Bartenschlager, R., L. Ahlborn-Laake, J. Mous, and H. Jacobsen. 1994. Kinetic and structural analyses of hepatitis C virus polyprotein processing. J. Virol. 68:5045-5055.
4. Boehringer Ingelheim (Canada), Ltd. August 2003. Macrocyclic peptides active against the hepatitis C virus. U.S. patent 6,608,027 B1.
5. Boehringer Ingelheim (Canada), Ltd. March 2003. Hepatitis C inhibitor tri-peptides. U.S. patent 6,534,523 B1.
6. Cicero, D. O., G. Barbato, U. Koch, P. Ingallinella, E. Bianchi, M. C. Nardi, C. Steinkuhler, R. Cortese, V. Matassa, R. De Francesco, A. Pessi, and R. Bazzo. 1999. Structural characterization of the interactions of optimized product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studies. J. Mol. Biol. 289:385-396.
7. Cornberg, M., H. Wedemeyer, and M. P. Manns. 2002. Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. Curr. Gastroenterol. Rep. 4:23-30.
8. De Francesco, R., G. Migliaccio, and G. Paonessa. August 2002. Hepatitis C virus replicons and replicon enhanced cells. WO patent 0259321.
9. Di Marco, S., M. Rizzi, C. Volpari, M. A. Walsh, F. Narjes, S. Colarusso, R. De Francesco, V. G. Matassa, and M. Sollazzo. 2000. Inhibition of the hepatitis C virus NS3/4A protease: the crystal structures of two protease-inhibitor complexes. J. Biol. Chem. 275:7152-7157.
10. Failla, C., L Tomei, and R. De Francesco. 1995. An amino-terminal domain of the hepatitis C virus NS3 protease is essential for interaction with NS4A. J. Virol. 69:1769-1777.
11. Foy, E., K. Li, C. Wang, R. Sumpter, Jr., M. Ikeda, S. M. Lemon, and M. G. Gale, Jr. 2003. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300:1145-1148.
12. Grakoui, A., C. Wychowski, C. Lin, S. M. Feinstone, and C. M. Rice. 1993. Expression and identification of hepatitis C virus polyprotein cleavage products. J. Virol. 67:1385-1395.
13. Ikeda, M., M. Yi, K. Li, and S. M. Lemon. 2002. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J. Virol. 76:2997-3006.
14. Kolykhalov, A. A., K. Mihalik, S. M. Feinstone, and C. M. Rice. 2000. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J. Virol. 74:2046-2051.
15. Krieger, N., V. Lohmann, and R. Bartenschlager. 2001. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 75:4614-4624.
16. Lamarre, D., P. C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bos, D. R. Cameron, M. Cartier, M. G. Cordingley, A.-M. Faucher, N. Goudreau, S. H. Kawai, G. Kukolj, L. Lagace, S. R. LaPlante, H. Narjes, M.-A. Poupart, J. Rancourt, R. E. Sentjens, R. St. George, B. Simoneau, G. Steinmann, D. Thibeault, Y. S. Tsantrizos, S. M. Weldon, C.-L. Yong, and M. Llinas-Brunet. 2003. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-189.
17. Llinas-Brunet, M., M. Bailey, G. Fazal, E. Ghiro, V. Gorys, S. Goulet, T. Halmos, R. Maurice, M. Poirier, M. A. Poupart, J. Rancourt, D. Thibeault, D. Wernic, and D. Lamarre. 2000. Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors. Bioorg. Med. Chem. Lett. 10:2267-2270.
18. Llinas-Brunet, M., M. Bailey, G. Fazal, S. Goulet, T. Halmos, S. Laplante, R. Maurice, M. Poirier, M. A. Poupart, D. Thibeault, D. Wernic, and D. Lamarre. 1998. Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorg. Med. Chem. Lett. 8:1713-1718.
19. Lohmann, V., F. Körner, A. Dobierzewska, and R. Bartenschlager. 2001. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J. Virol. 75:1437-1449.
20. Mo, H., L. Lu, T. Dekhtyar, K. D. Stewart, E. Sun, D. J. Kempf, and A. Molla. 2003. Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir. Antivir. Res. 59:173-180.
21. Molla, A., M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H. M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
22. Narjes, F., U. Koch, and C. Steinkuhler. 2003. Recent developments in the discovery of hepatitis C virus serine protease inhibitors-towards a new class of antivirial agents? Expert Opin. Investig. Drugs 12:153-163.
23. Neddermann, P., L. Tomei, C. Steinkuhler, P. Gallinari, A. Tramontano, and R. De Francesco. 1997. The non-structural proteins of hepatitis C virus: structure and functions. Biol. Chem. 378:469-476.
24. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
25. Pizzi, E., A. Tramontano, L. Tomei, N. La Monica, C. Failla, M. Sardana, T. Wood, and R. De Francesco. 1994. Molecular model of the specificity pocket of the hepatitis C virus protease: implications for substrate recognition. Proc. Natl. Acad. Sci. USA 91:888-892.
26. Steinkuhler, C., U. Koch, F. Narjes, and V. G. Matassa. 2001. Hepatitis C virus protease inhibitors: current progress and future challenges. Curr. Med. Chem. 8:919-932.
27. Trozzi, C., L. Bartholomew, A. Ceccacci, G. Biasiol, L. Pacini, S. Altamura, F. Narjes, E. Muraglia, G. Paonessa, U. Koch, R. De Francesco, C. Steinkuhler, and G. Migliaccio. 2003. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J. Virol. 77:3669-3679.
28. Tsantrizos, Y. S., G. Bolger, P. Bonneau, D. R. Cameron, N. Goudreau, G. Kukolj, S. R. LaPlante, M. Llinas-Brunet, H. Nar, and D. Lamarre. 2003. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew. Chem. Int. Ed. Engl. 42:1356-1360.
29. Wright, M., J. Main, and H. C. Thomas. 2001. Treatment of chronic viral hepatitis. Antivir. Chem. Chemother. 12:201-212.
30. Yan, Y., Y. Li, S. Munshi, V. Sardana, J. L. Cole, M. Sardana, C. Steinkuehler, L. Tomei, R. De Francesco, L. C. Kuo, and Z. Chen. 1998. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 Å resolution structure in a hexagonal crystal form. Protein Sci. 7:837-847.
31. Yao, N., P. Reichert, S. S. Taremi, W. W. Prosise, and P. C. Weber. 1999. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Struct. Fold Des. 7:1353-1363.
32. Yi, M., F. Bodola, and S. M. Lemon. 2002, Subgenomic hepatitis C virus replicons inducing expression of a secreted enzymatic reporter protein. Virology 304:197-210.